Journal article · 2018 · Open access

Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer

Abhishek Gangrade, Vibha Pathak, Corinne E. Augelli‐Szafran, Han‐Xun Wei, Patsy G. Oliver, Mark J. Suto, Donald J. Buchsbaum

International Journal of Molecular Sciences, 19(5), 1524 · Published 20 May 2018 · DOI 10.3390/ijms19051524

Open PDFView at the publisherCite this paper

In brief

“Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer” is a 2018 journal article by Abhishek Gangrade and 6 co-authors, published in International Journal of Molecular Sciences. OpenAlex counts 52 citations as of 21 November 2026, which puts it in the top 9% of works published in 2018 by citations. It is open access under a CC BY licence: the full text is free to read at International Journal of Molecular Sciences.

Citations
52
Most cited in
2020 (11)
Field-weighted impact
1.87
References
75
Authors
7

Abstract

Wnt/β-catenin signaling is upregulated in triple-negative breast cancer (TNBC) compared to other breast cancer subtypes and normal tissues. Current Wnt/β-catenin inhibitors, such as niclosamide, target the pathway nonspecifically and exhibit poor pharmacokinetics/pharmacodynamics in vivo. Niclosamide targets other pathways, including mTOR, STAT3 and Notch. Novel benzimidazoles have been developed to inhibit Wnt/β-catenin signaling with greater specificity. The compounds SRI33576 and SRI35889 were discovered to produce more cytotoxicity in TNBC cell lines than in noncancerous cells. The agents also downregulated Wnt/β-catenin signaling mediators LRP6, cyclin D1, survivin and nuclear active β-catenin. In addition, SRI33576 did not affect mTOR, STAT3 and Notch signaling in TNBC and noncancerous cells. SRI35889 inhibited mTOR signaling less in noncancerous than in cancerous cells, while not affecting STAT3 and Notch pathways. Compounds SRI32529, SRI35357 and SRI35361 were not selectively cytotoxic against TNBC cell lines compared to MCF10A cells. While SRI32529 inhibited Wnt/β-catenin signaling, the compound also mitigated mTOR, STAT3 and Notch signaling. SRI33576 and SRI35889 were identified as cytotoxic and selective inhibitors of Wnt/β-catenin signaling with therapeutic potential to treat TNBC in vivo.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Gangrade, A., Pathak, V., Augelli‐Szafran, C. E., Wei, H., Oliver, P. G., Suto, M. J., & Buchsbaum, D. J. (2018). Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 19(5), 1524. https://doi.org/10.3390/ijms19051524

MLA 9

Gangrade, Abhishek, et al. “Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.” International Journal of Molecular Sciences, vol. 19, no. 5, 2018, p. 1524. https://doi.org/10.3390/ijms19051524.

Chicago

Gangrade, Abhishek, Vibha Pathak, Corinne E. Augelli‐Szafran, Han‐Xun Wei, Patsy G. Oliver, Mark J. Suto, and Donald J. Buchsbaum. 2018. “Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.” International Journal of Molecular Sciences 19 (5): 1524. https://doi.org/10.3390/ijms19051524.

Harvard

Gangrade, A. et al. (2018) ‘Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer’, International Journal of Molecular Sciences, 19(5), p. 1524. doi:10.3390/ijms19051524.

IEEE

A. Gangrade et al., “Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer,” International Journal of Molecular Sciences, vol. 19, no. 5, p. 1524, 2018, doi: 10.3390/ijms19051524.

BibTeX

@article{gangrade2018preferential,
  title     = {{Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer}},
  author    = {Gangrade, Abhishek and Pathak, Vibha and Augelli‐Szafran, Corinne E. and Wei, Han‐Xun and Oliver, Patsy G. and Suto, Mark J. and Buchsbaum, Donald J.},
  journal   = {International Journal of Molecular Sciences},
  year      = {2018},
  volume    = {19},
  number    = {5},
  pages     = {1524},
  doi       = {10.3390/ijms19051524},
  url       = {https://doi.org/10.3390/ijms19051524}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201988
20201111
202177
202288
202366
202466
202555
202611

Its field-weighted citation impact is 1.87: it has been cited 1.87 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer

  • Wnt/β-catenin signaling
  • triple-negative breast cancer
  • niclosamide
  • LRP6
  • cyclin D1
  • survivin
  • mTOR signaling
  • STAT3 signaling

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Gangrade, A., Pathak, V., Augelli‐Szafran, C. E., Wei, H., Oliver, P. G., Suto, M. J., & Buchsbaum, D. J. (2018). Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 19(5), 1524. https://doi.org/10.3390/ijms19051524

How many times has this paper been cited?

52 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at International Journal of Molecular Sciences: sign in and open the PDF from this page.

Who wrote this paper?

Abhishek Gangrade, Vibha Pathak, Corinne E. Augelli‐Szafran, Han‐Xun Wei, Patsy G. Oliver, Mark J. Suto, Donald J. Buchsbaum.

What is the DOI of this paper?

10.3390/ijms19051524, permanently at https://doi.org/10.3390/ijms19051524. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.